Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Zoom
ZM
|
+$96M |
| 2 |
Match Group
MTCH
|
+$81.3M |
| 3 |
Peloton Interactive
PTON
|
+$75.6M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
+$55.6M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$50.7M |
Top Sells
| 1 |
Apple
AAPL
|
+$201M |
| 2 |
Microsoft
MSFT
|
+$112M |
| 3 |
IAC Inc
IAC
|
+$77.1M |
| 4 |
Amazon
AMZN
|
+$73.4M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$52.8M |
Sector Composition
| 1 | Technology | 26.26% |
| 2 | Healthcare | 14.68% |
| 3 | Consumer Discretionary | 13.69% |
| 4 | Communication Services | 10.36% |
| 5 | Industrials | 8.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1776
Columbus McKinnon
CMCO
$423M
| $1.78M | ﹤0.01% |
53,911
+1,000
| +2% | +$33.1K |
|
1777
Sapiens International
SPNS
$2.4B
| $1.78M | ﹤0.01% |
57,136
| – | – |
|
1778
ArcBest
ARCB
$1.66B
| $1.78M | ﹤0.01% |
57,300
+600
| +1% | +$18.6K |
|
1779
Trinseo
TSE
$86.6M
| $1.78M | ﹤0.01% |
69,300
+900
| +1% | +$23.1K |
|
1780
Douglas Dynamics
PLOW
$762M
| $1.77M | ﹤0.01% |
51,800
+900
| +2% | +$30.8K |
|
1781
Travere Therapeutics
TVTX
$2.23B
| $1.77M | ﹤0.01% |
95,700
+1,700
| +2% | +$31.4K |
|
1782
Enanta Pharmaceuticals
ENTA
$186M
| $1.76M | ﹤0.01% |
38,500
+700
| +2% | +$32.1K |
|
1783
ACM Research
ACMR
$1.91B
| $1.76M | ﹤0.01% |
76,200
| – | – |
|
1784
Angi Inc
ANGI
$781M
| $1.75M | ﹤0.01% |
15,810
-1,420
| -8% | -$158K |
|
1785
Southside Bancshares
SBSI
$918M
| $1.75M | ﹤0.01% |
71,718
| – | – |
|
1786
First Busey Corp
BUSE
$2.19B
| $1.75M | ﹤0.01% |
110,099
| – | – |
|
1787
Veritex Holdings
VBTX
$1.87B
| $1.75M | ﹤0.01% |
102,617
| – | – |
|
|
RAVN
1788
DELISTED
Raven Industries Inc
RAVN
| $1.75M | ﹤0.01% |
81,200
+1,400
| +2% | +$30.1K |
|
|
ALEX
1789
Alexander & Baldwin
ALEX
$1.37B
| $1.75M | ﹤0.01% |
155,720
+2,300
| +1% | +$25.8K |
|
1790
National Healthcare
NHC
$1.78B
| $1.73M | ﹤0.01% |
27,830
+500
| +2% | +$31.2K |
|
1791
Celestica
CLS
$28.6B
| $1.73M | ﹤0.01% |
251,700
+4,700
| +2% | +$32.3K |
|
1792
JetBlue
JBLU
$1.86B
| $1.73M | ﹤0.01% |
152,800
+2,300
| +2% | +$26.1K |
|
1793
Y-mAbs Therapeutics
YMAB
$390M
| $1.73M | ﹤0.01% |
45,100
+700
| +2% | +$26.9K |
|
1794
Tompkins Financial
TMP
$1B
| $1.73M | ﹤0.01% |
30,400
+300
| +1% | +$17K |
|
1795
First Commonwealth Financial
FCF
$1.84B
| $1.72M | ﹤0.01% |
222,400
+2,900
| +1% | +$22.4K |
|
|
ENDP
1796
DELISTED
Endo International plc
ENDP
| $1.72M | ﹤0.01% |
520,600
+14,300
| +3% | +$47.2K |
|
1797
Orion
OEC
$578M
| $1.7M | ﹤0.01% |
136,100
| – | – |
|
1798
Vericel Corp
VCEL
$1.68B
| $1.7M | ﹤0.01% |
91,700
+1,400
| +2% | +$25.9K |
|
|
CATM
1799
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $1.7M | ﹤0.01% |
85,700
+1,000
| +1% | +$19.8K |
|
1800
Karyopharm Therapeutics
KPTI
$55.9M
| $1.69M | ﹤0.01% |
7,737
+907
| +13% | +$199K |
|